Clinical Trials Logo

Adult Growth Hormone Deficiency clinical trials

View clinical trials related to Adult Growth Hormone Deficiency.

Filter by:

NCT ID: NCT02946606 Completed - Clinical trials for Adult Growth Hormone Deficiency

A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9

Start date: January 2015
Phase: Phase 2
Study type: Interventional

This is a randomized, active-controlled, open-label, sequential dose group, Phase 1b/2 study designed to assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of weekly and every other week doses of GX-H9 in the treatment of AGHD.

NCT ID: NCT02526420 Completed - Clinical trials for Adult Growth Hormone Deficiency

Versartis International Trial in Adults With Long-Acting Growth Hormone

VITAL
Start date: July 2015
Phase: Phase 2
Study type: Interventional

A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.

NCT ID: NCT02382939 Completed - Clinical trials for Adult Growth Hormone Deficiency

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

REAL 2
Start date: February 12, 2015
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe and Asia. The aim of the trial is to compare the safety of once weekly dosing of somapacitan (administered with an investigational pen) with daily Norditropin® FlexPro® (somatropin delivered within a prefilled pen) for 26 weeks in previously human growth hormone (hGH) treated adults with growth hormone deficiency.

NCT ID: NCT02229851 Completed - Clinical trials for Adult Growth Hormone Deficiency

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

REAL 1
Start date: October 31, 2014
Phase: Phase 3
Study type: Interventional

This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.

NCT ID: NCT02005198 Completed - Clinical trials for Adult Growth Hormone Deficiency

Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

Start date: March 2014
Phase: N/A
Study type: Observational

This study is conducted in the United States of America (USA). The aim of the study is to assess the minimal important difference (MID) of the TRIM-AGHD.

NCT ID: NCT01909479 Terminated - Clinical trials for Adult Growth Hormone Deficiency

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

Start date: June 2013
Phase: Phase 3
Study type: Interventional

This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).

NCT ID: NCT01822340 Completed - Clinical trials for Adult Growth Hormone Deficiency

Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients

HM10560A
Start date: October 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and Pharmacokinetic/ Pharmacodynamic (PK/PD) profile of three doses of HM10560A on an every week (EW) regime and one dose on every other week (EOW) regime administered for a period of 24 weeks initial study.

NCT ID: NCT01806298 Completed - Clinical trials for Adult Growth Hormone Deficiency

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)

Start date: June 2013
Phase: Phase 4
Study type: Interventional

This is an open-label, single-arm, multicenter, Phase 4 study to explore the immunogenicity of the liquid formulation of Saizen® in subjects with Adult Growth Hormone Deficiency (AGHD), who are growth hormone (GH) treatment-naïve or who had prior GH treatment for GHD which was stopped at least 1 month prior to Screening and have no contraindication to the use of GH.

NCT ID: NCT01706783 Completed - Clinical trials for Adult Growth Hormone Deficiency

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Start date: October 12, 2012
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (NNC0195-0092, somapacitan) compared to once daily Norditropin NordiFlex® in adults with growth hormone deficiency (GHD).

NCT ID: NCT01698944 Terminated - Clinical trials for Adult Growth Hormone Deficiency

Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency

Start date: May 16, 2001
Phase: Phase 4
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to investigate the effect of growth hormone on left ventricle morphology and function (systolic and diastolic).